

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Caroline Munk Esbjerg				
2	Reason for the notification					
a)	Position/status	Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333				
b)	Nature of the transaction	Shares received as gift				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 294.30</td> <td>50</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 294.30	50
Price(s)	Volume(s)					
DKK 294.30	50					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	50 shares DKK 14,715				
e)	Date of the transaction	2026-05-07				
f)	Place of the transaction	Outside a trading venue				

1		Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Sofie Munk Esbjerg	
2		Reason for the notification	
a)	Position/status	Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)	
b)	Initial notification/Amendment	Initial notification	
3		Details of the issuer	
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4		Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Shares received as gift	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.25	50
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	50 shares DKK 14,712.50	
e)	Date of the transaction	2026-05-07	
f)	Place of the transaction	Outside a trading venue	

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#)

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

Investors:

Michael Novod

+45 3075 6050

nvno@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

Max Ung

+45 3077 6414

mxun@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Alex Bruce

+45 3444 2613

axeu@novonordisk.com

Christoffer Sho Togo Tullin

+45 3079 1471

cftu@novonordisk.com

Mads Berner Bruun

+45 3075 2936

mbbz@novonordisk.com

Frederik Taylor Pitter

+1 609 613 0568

fptr@novonordisk.com